Literature DB >> 23022399

A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles.

Dharmendra Raghuwanshi1, Vivek Mishra, Mavanur R Suresh, Kamaljit Kaur.   

Abstract

In this study, we demonstrate a simple strategy for enhanced immune response using a two-component dendritic cell (DC) targeted antigen delivery system. One component consists of a recombinant bifunctional fusion protein (bfFp) used for DC targeting, whereas, the other component is made of biotinylated PLGA nanoparticles that encapsulate the antigen. The fusion protein (bfFp) made of a truncated core-streptavidin fused to anti-DEC-205 single chain antibody (scFv) was mixed with ovalbumin-loaded biotinylated NPs that were formulated using biotin-PEG (2000)-PLGA, and the combination, bfFp functionalized NPs was used for DC targeted antigen delivery. In vitro DC uptake studies revealed a 2-fold higher receptor-mediated uptake of bfFp functionalized NPs when compared to non-targeted NPs. Immunization of the mice with the bfFp functionalized NPs in conjunction with DC maturation stimulus (anti-CD40 mAb) enhanced OVA-specific IgG and IgG subclass responses. Splenocytes of these mice secreted significantly higher levels of Th1 (IFN-γ and IL-2) cytokines upon ex vivo restimulation with OVA. The promising outcomes of the bfFp functionalized DC targeted system support its use as a versatile vaccine delivery system for the design of monovalent or polyvalent vaccines.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23022399     DOI: 10.1016/j.vaccine.2012.09.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Activation of Antigen-Specific CD8(+) T Cells by Poly-DL-Lactide/Glycolide (PLGA) Nanoparticle-Primed Gr-1(high) Cells.

Authors:  Wen-Hui Luo; Ya-Wun Yang
Journal:  Pharm Res       Date:  2015-12-29       Impact factor: 4.200

Review 2.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

Review 3.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

4.  Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.

Authors:  Michael-Joseph Gorbet; Akansha Singh; Chenkai Mao; Steven Fiering; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

5.  Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.

Authors:  Matthias Wölfl; Stefanie Schwinn; Young-Eun Yoo; Marie L Reß; Matthias Braun; Martin Chopra; Susanne C Schreiber; Victor I Ayala; Claes Ohlen; Matthias Eyrich; Andreas Beilhack; Paul G Schlegel
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

Review 6.  Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.

Authors:  Luo Gu; David J Mooney
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

Review 7.  The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.

Authors:  Akshay Jain; Kun Cheng
Journal:  J Control Release       Date:  2016-11-16       Impact factor: 9.776

8.  In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy.

Authors:  Xu-Dong Tang; Kui-Lin Lü; Jin Yu; Han-Jian Du; Chao-Qiang Fan; Lei Chen
Journal:  Cancer Immunol Immunother       Date:  2022-05-12       Impact factor: 6.630

Review 9.  Engineered nanomaterial exposure and the risk of allergic disease.

Authors:  Jonathan H Shannahan; Jared M Brown
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-04

Review 10.  Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses.

Authors:  Vijaya B Joshi; Sean M Geary; Aliasger K Salem
Journal:  Hum Vaccin Immunother       Date:  2013-08-26       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.